Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising results in preliminary clinical trials . Current https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/